Bethany J. Cavanagh

CIK: 0002033155

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)9 (60.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

BEAM

Beam Therapeutics Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (15 total)

BEAM
Beam Therapeutics Inc.
Oct 1, 2026
Sale(S)
Direct
187 shares at avg. $24.41$5K
BEAM
Beam Therapeutics Inc.
Apr 1, 2026
Sale(S)
Direct
3.2K shares at avg. $24.58$80K
BEAM
Beam Therapeutics Inc.
Mar 31, 2026
Award(A)
Direct
20K shares-
BEAM
Beam Therapeutics Inc.
Jan 31, 2026
Award(A)
Stock Option (Right to Buy)
Direct
40K shares-
BEAM
Beam Therapeutics Inc.
Jan 22, 2026
Sale(S)
Direct
6.2K shares at avg. $35.00$217K
BEAM
Beam Therapeutics Inc.
Jan 20, 2026
Sale(S)
Direct
3K shares at avg. $30.12$91K
BEAM
Beam Therapeutics Inc.
Oct 1, 2025
Sale(S)
Direct
467 shares at avg. $24.53$11K
BEAM
Beam Therapeutics Inc.
Apr 1, 2025
Sale(S)
Direct
3K shares at avg. $18.35$55K
BEAM
Beam Therapeutics Inc.
Mar 31, 2025
Award(A)
Direct
10K shares-
BEAM
Beam Therapeutics Inc.
Feb 18, 2025
Sale(S)
Direct
6.3K shares at avg. $35.00$220K
BEAM
Beam Therapeutics Inc.
Jan 31, 2025
Award(A)
Stock Option (Right to Buy)
Direct
20K shares-
BEAM
Beam Therapeutics Inc.
Jan 2, 2025
Sale(S)
Direct
1.1K shares at avg. $24.68$28K
BEAM
Beam Therapeutics Inc.
Oct 1, 2024
Sale(S)
Direct
289 shares at avg. $23.48$7K
BEAM
Beam Therapeutics Inc.
Sep 30, 2024
Award(A)
Direct
2.5K shares-
BEAM
Beam Therapeutics Inc.
Aug 31, 2024
Award(A)
Stock Option (Right to Buy)
Direct
5K shares-

		Type	Shares	Price		Ownership
Oct 1, 2026	BEAM Beam Therapeutics Inc.	Sale(S)	187	$24.41	$4,565	Direct
Apr 1, 2026	BEAM Beam Therapeutics Inc.	Sale(S)	3,242	$24.58	$79,688	Direct
Mar 31, 2026	BEAM Beam Therapeutics Inc.	Award(A)	20,000	-	$0	Direct
Jan 31, 2026	BEAM Beam Therapeutics Inc.	Award(A) Stock Option (Right to Buy)	40,000	-	-	Direct
Jan 22, 2026	BEAM Beam Therapeutics Inc.	Sale(S)	6,198	$35.00	$216,933	Direct
Jan 20, 2026	BEAM Beam Therapeutics Inc.	Sale(S)	3,034	$30.12	$91,384	Direct
Oct 1, 2025	BEAM Beam Therapeutics Inc.	Sale(S)	467	$24.53	$11,456	Direct
Apr 1, 2025	BEAM Beam Therapeutics Inc.	Sale(S)	3,015	$18.35	$55,330	Direct
Mar 31, 2025	BEAM Beam Therapeutics Inc.	Award(A)	10,000	-	-	Direct
Feb 18, 2025	BEAM Beam Therapeutics Inc.	Sale(S)	6,287	$35.00	$220,045	Direct
Jan 31, 2025	BEAM Beam Therapeutics Inc.	Award(A) Stock Option (Right to Buy)	20,000	-	-	Direct
Jan 2, 2025	BEAM Beam Therapeutics Inc.	Sale(S)	1,117	$24.68	$27,568	Direct
Oct 1, 2024	BEAM Beam Therapeutics Inc.	Sale(S)	289	$23.48	$6,785	Direct
Sep 30, 2024	BEAM Beam Therapeutics Inc.	Award(A)	2,500	-	$0	Direct
Aug 31, 2024	BEAM Beam Therapeutics Inc.	Award(A) Stock Option (Right to Buy)	5,000	-	-	Direct

1-15 of 15 transactions

About Cavanagh Bethany J

Cavanagh Bethany J (SEC CIK 0002033155) files insider reports with the SEC as SVP, Finance and Treasurer of Beam Therapeutics Inc. (BEAM).

Signal8 holds 14 ownership filings by Cavanagh Bethany J, all Form 4s, filed between Sep 3, 2024 and Oct 2, 2026. Those filings report 15 transactions, from Aug 31, 2024 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Cavanagh Bethany J's filings is in CAMBRIDGE, MA.

Recent filings by Cavanagh Bethany J

Oct 1, 2026: Open-market sale of BEAM shares (Form 4, code S).
Apr 1, 2026: Open-market sale of BEAM shares (Form 4, code S).
Mar 31, 2026: Grant or award of BEAM shares (Form 4, code A).
Jan 31, 2026: Grant or award of BEAM derivative securities (Form 4, code A).
Jan 22, 2026: Open-market sale of BEAM shares (Form 4, code S).

Other insiders filing for Beam Therapeutics Inc. (BEAM)

Evans John M., CEO
Ciaramella Giuseppe, President
Simon Amy, Chief Medical Officer
FMR LLC, 10% Owner
Shaw Christi, Director
Walsh Kathleen E, Director

How to read Form 4 transaction codes